RxDoctor Payments Data

Shannon Oien

Nurse Practitioner · Loma Linda, CANPI 1568484723

Payments from drug & device makers

$1,118in general payments, 2019–2025

Across 24 payments — averaging $46.58 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Medtronic$720
  • AbbVie$128
  • Bayer$75
  • Boston Scientific$47
  • Novo Nordisk$41
  • Urogen Pharma, Inc.$34
  • plus $73 from 3 others

What the payments were for

  • Travel & lodging$46041%
  • Food & beverage$65859%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Medtronic10$720
AbbVie5$128
Bayer1$75
Boston Scientific2$47
Novo Nordisk2$41
Urogen Pharma, Inc.1$34
Sumitomo Pharma America, Inc.1$29
Teleflex LLC1$25
Cycle Pharmaceuticals Inc1$19

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,118 in reported general payments places this provider in the 80th percentile of 6,779 nurse practitioner providers in California.

See all nurse practitioner providers in California

Medicare billing

Part B allowed, 2024
$58,725
Medicare patients
304
Services billed
868

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
GemtesaVibegron52$43,698
MyrbetriqMirabegron28$24,931
Methenamine Hippurate91$9,021
Bethanechol Chloride12$4,094
Solifenacin Succinate42$2,780
Tamsulosin Hcl183$2,131
Estradiol16$1,869
Finasteride74$1,004
Oxybutynin Chloride38$777
Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst22$502
Cephalexin12$133
Sulfamethoxazole-TrimethoprimSulfamethoxazole/Trimethoprim19$98
Ciprofloxacin Hcl23$82

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Sumitomo Pharma America, Inc.Gemtesa$29$43,69852 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 6,779 nurse practitioner providers in California.

Other nurse practitioner in Loma Linda

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →